AOA Dx Inc has partnered with a leading researcher at McGill University to develop the first early stage ovarian cancer liquid biopsy diagnostic test. The co-founders have worked together at two previous startups in the women’s health space, both resulting in successful exits upon commercialization. Ovarian cancer is the deadliest gynecological disease because there is no accurate testing method and therefore its symptoms are continuously mistaken for benign conditions, making it incredibly difficult to diagnose the disease in the early stages. The team has previously raised a $7M Seed round and completed a 400+ retrospective patient study showing excellent sensitivity and specificity. Ovarian cancer is just the beginning. AOA has a platform of novel ganglioside tumor markers to disrupt early cancer detection. AOA Dx is currently developing their assay and conducting further clinical studies.
Recently, Oriana Papin-Zohgbi, the company’s Co-founder and CEO, met with Mansfield Bio-Incubator’s Advisory Board as part of the routine check-in with the member companies. “I had a great meeting with our Advisory Board at Mansfield Bio-Incubator to brainstorm fundraising strategy and growing our company! Excited to continue working with this team.”
Mansfield Bio-Incubator is excited to have AOA Dx as our member company and is committed to supporting their work to ensure their success. They are currently hiring a Director of Clinical Operations: https://www.aoadx.com/clinical-director-operations.
For more information, visit their website at https://www.aoadx.com/.